Search for: "Kirin v. Kirin"
Results 61 - 80
of 83
Sorted by Relevance
|
Sort by Date
14 Nov 2019, 6:43 am
Guestkat Rose Hughes walked us through the court's reasoning in relation to the Biogen and Kirin-Amgen cases.GuestKat Rose Hughes responded to an anonymous Katfriend tipper and reported on an interesting update in the progress of the CRISPR/Broad Institute appeal (T0844/18). [read post]
18 Dec 2023, 3:05 am
On 14 December 2023 there was a set aside application in the case of McGee v Lewis before Collins Rice J. [read post]
19 Mar 2014, 9:00 am
It has been 15 years since the last brand v brand challenge of a biologic patent in Canada. [read post]
9 Apr 2009, 7:52 am
(IP Think Tank) Brazilian public-private partnerships in the pharma industry (IP tango) EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog) India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? [read post]
25 Mar 2016, 2:11 pm
FKB, a joint venture between FUJIFILM and Kyowa Hakko Kirin, intends to clear the path of AbbVie's follow-on patents in order to market its biosimilar adalimumab product after expiry of the UK SPC in October 2018. [read post]
27 Oct 2010, 3:38 am
General GSK forms alliance for development of gene therapy techniques for rare diseases (Patent Docs) Emerging economies’ new initiative on falsified and substandard medicines (IP Watch) Michèle Rivasi asks question about ACTA and Access to Medicine (KEI) As negotiators launch talks on biodiversity, industry requests IP protection (IP Watch) Negotiators persist on biodiversity benefit-sharing treaty despite slipping deadlines (IP Watch) New draft biodiversity treaty text shows much work… [read post]
28 Jan 2010, 7:49 am
, Inc. v. [read post]
12 Dec 2014, 5:06 am
It won’t do if you are thinking of claim where the product is not actually new as such (such as erythropoietin in the Kirin Amgen case). [read post]
26 Jan 2015, 9:57 pm
Category: Civil Procedure By: Roy Rabindranath, Contributor TitleJapanese Found. for Cancer Research v. [read post]
18 Jul 2012, 4:52 am
" "The second is that it is necessary to distinguish between claims that are difficult to construe or that have a "fuzzy boundary" (in the words of Lord Hoffmann in Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2004] UKHL 46, [2005] RPC 9 at [126]) on the one hand from claims that are truly ambiguous on the other. [read post]
10 Aug 2012, 8:33 am
" (Virgin v Premium Aircraft). [read post]
3 Jul 2011, 11:08 pm
& Filmworks, Inc. v. [read post]
2 Jul 2009, 11:51 am
An example of an insufficiency of this type is the molecular weight test in Kirin Amgen at [121] which made it impossible to tell whether there was infringement or not. [read post]
19 Apr 2017, 2:21 am
Much of the hearing was therefore taken up by submissions on the proper approach to take on claim construction in view of EPC 2000 and the seminal UK cases of Catnic [1982] R.P.C. 183, Improver [1990] F.S.R. 181 and Kirin-Amgen [2004] UKHL 46. [read post]
24 Oct 2022, 1:00 am
On whether a particle is dish-shaped, the Judge indicated that both Kirin-Amgen [2004] UKHL 46 and Anan Kasei [2019] EWCA Civ 1646 distinguished a fuzzy boundary from conceptual uncertainty. [read post]
25 Jan 2017, 10:48 pm
Andrew considered that Regeneron v Kymab [2016] EWHC 87 (Pat) represented the most technically difficult decision of the year, although he noted that Electromagnetic Geoservices v PGS would have run it pretty close had the case not settled. [read post]
6 Sep 2010, 12:42 am
Kirin Amgen Inc. v Lietuvos Respublikos valstybinis patent? [read post]
1 Jan 2014, 4:33 am
According to the recent Generics v Teva/Yeda decision, the burden of proof should therefore be on the alleged infringer, not the patentee. [read post]
13 Aug 2019, 4:20 pm
Rik LambersWhile the numerous recent court decisions may suggest so, the ‘F’ in FRAND does not stand for ‘Fashionable’. [read post]
14 May 2013, 12:22 am
The subject of Norman's guest post here is the recent US decision in CLS Bank Int’l v Alice Corp 2011-1301 (Fed Cir 2013) en banc aff’g 768 F Supp 2d 221 (D.D.C. 2011). [read post]
